Plerixafor
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Plerixafor: From Plasma Cell Myeloma to Indolent Plasma Cell Myeloma
One-Sentence Summary
Plerixafor was originally used in plasma cell myeloma, where it mobilises stem cells for autologous transplant. The TxGNN model predicts it may be effective for indolent plasma cell myeloma, but no clinical trials and no publications specific to this subtype were found, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Plasma cell myeloma (stem cell mobilisation for autologous transplant) |
| Predicted New Indication | Indolent plasma cell myeloma |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Plerixafor is a CXCR4 antagonist, and it also acts on ACKR3. CXCR4/CXCL12 signalling anchors myeloma cells in the bone marrow. Blocking this axis releases cells from the marrow niche. This is how plerixafor works as a stem cell mobiliser, given together with G-CSF before autologous transplant. Detailed mechanism-of-action data are not otherwise available in the compiled data.
The original and predicted indications are closely related, since both are plasma cell disorders. The high TxGNN score most likely reflects this proximity rather than independent evidence. Plerixafor's established myeloma use is stem cell mobilisation, not treatment of the disease itself. In indolent disease, which is usually observed or treated lightly, a mobilising agent has no clear therapeutic role.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13894P | Mozobil Solution for Injection 20mg/ml (Genzyme Corporation) | Injection, solution | Not stated in the registration record |
| SIN16879P | Pleristem Solution for Injection 20mg/ml (Eugia Pharma Specialities Limited) | Injection, solution | Not stated in the registration record |
| SIN17147P | Plerixafor-AFT Solution for Injection 24 mg/1.2 mL (Sichuan Huiyu Pharmaceutical Co., Ltd.) | Injection, solution | Not stated in the registration record |
All three licences are valid single-ingredient products.
Safety Considerations
- Contraindication-related conditions (knowledge-graph level, not label text): thrombocytopenia, impaired renal function and leukaemia. These come from drug-disease relationships in the TxGNN knowledge graph and should be checked against the approved package insert.
Please refer to the package insert for further safety information, including warnings and drug interactions.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for indolent plasma cell myeloma is supported only by the model score and a general CXCR4 mechanism. There are no trials or publications for this subtype, and plerixafor's role in myeloma is mobilisation rather than disease treatment.
To proceed, the following is needed:
- Clinical or literature evidence specific to indolent or smouldering myeloma, such as a rationale for a therapeutic role beyond mobilisation
- Full package insert warnings and contraindications from HSA, and mechanism-of-action data
- A clear clinical question defining the intended use, population and dosing
Note on other predictions: The same analysis ranks myeloid leukaemia (score 99.02%) with 25 registered trials and 20 publications. These are mostly Phase 1 and Phase 1/2 studies of plerixafor as a chemosensitiser in acute myeloid leukaemia (for example NCT00512252 and NCT00906945, plus the Blood 2012 Phase 1/2 study, PMID 22308295). That evidence is graded L2 and flagged as a research question, but it lacks randomised or Phase 3 data. If the aim is to find the best-supported repurposing direction for plerixafor, this indication is a more productive area to evaluate. Note that the knowledge graph also lists leukaemia among contraindication-related conditions, which would need to be resolved first.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.